Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects

NCT00146328 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

997

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Tipranavir

Sponsor

Boehringer Ingelheim